Scynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.
In the latest article from SIDP, here is a look at therapy options addressing this emerging clinical challenge.
The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.
Catherine Chappell, MD, MSc, presents what we know so far, highlighting the safety and effectiveness of direct-acting antivirals, the importance of shared decision-making, and the need for patient-provider discussions to ensure informed choices about care.
Corey Fishman and Steven Aronin, MD, discussed trial highlights of Orlynvah for uncomplicated urinary tract infections and outlining plans to seek partners for a market launch to address antibiotic resistance and enhance patient treatment options.
A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Vibrant Wellness’ Jason Barker, ND, outlines prevention measures, diagnostic red flags, and advances in multiplex testing for tick-borne diseases.
InflaRx CEO Niels Riedemann, MD, discusses the issue that arose and cost the company some of its data for its investigational therapy being studied for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
The COVID-19 pandemic underscored the urgent need for global pandemic preparedness. The World Health Organization (WHO) is leading efforts to establish a global treaty to address future pandemics, with findings expected in 2025. Central to this preparedness is immunomics, a field leveraging advanced genomics technologies to study the immune system at unprecedented levels of detail.
Will this winter bring the feared twindemic of SARS-CoV-2 and influenza, or will another common infection reemerge?
In a new study presented at MAD-ID, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population.
Chad Costley, MD, MPH, discussed the platform's ability to respond to emerging respiratory diseases and the challenges in advancing mucosal vaccine development for health preparedness.
Colleen Kelley, MD, MPH, offers some insights on where we are today with the state of HIV prevention including the expanding PrEP options, why PEP is underutilized, and the challenges behind HIV vaccine development.
Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
Similar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.
WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.
Implications for antimicrobial use and antimicrobial resistance.
As with other metallo-β-lactamases, NDM is capable of hydrolyzing nearly all β-lactams, including carbapenems, and the search for the proper antimicrobials is challenging.
Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.
Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.
Sarah Rowan, MD, on minimal laboratory testing, Hepatitis B screening flexibility, peer navigation, and state‑specific strategies to overcome outreach and reimbursement hurdles
Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.
Vaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.
The ideal parameter for vancomycin monitoring is the area under the curve, which can be calculated using pharmacokinetic equations or Bayesian software.
Here are some strategies to consider for optimal utilization.
This crisis has united multidisciplinary groups and laid the foundation to better equip the health care workforce for future pandemics.
A preview of our August 2021 issue Chairman’s Letter.
In the second part of our conversation, Abdulwhab Shremo Msdi, PharmD, discusses using this methodology.